Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus extended-release - Veloxis Pharmaceuticals

Drug Profile

Tacrolimus extended-release - Veloxis Pharmaceuticals

Alternative Names: Envarsus; Envarsus PA; EnvarsusXR; LCP-Tacro™; Tacrolimus extended release; Tacrolimus-ER

Latest Information Update: 26 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LifeCycle Pharma
  • Developer Chiesi Farmaceutici; Endo International; LifeCycle Pharma; University of Kentucky; University of Wisconsin-Madison; Veloxis Pharmaceuticals
  • Class Antiasthmatics; Antipsoriatics; Lactones; Macrolides; Skin disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Allotransplant rejection; Liver transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II/III Pancreas transplant rejection; Renal failure
  • Discontinued Autoimmune hepatitis

Most Recent Events

  • 22 Feb 2019 Registered for Liver transplant rejection (In adults, Prevention) in Canada (PO)
  • 22 Feb 2019 Registered for Renal transplant rejection (In adults, Prevention) in Canada (PO)
  • 01 Feb 2019 Phase-II/III clinical trials in Renal and Pancreas transplant rejection (Monotherapy) in USA (PO) (NCT03769298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top